The Asia Pacific Facial Injectable Market would witness market growth of 11.1% CAGR during the forecast period (2023-2029).
With an anticipated strong increase during the projected period, the cosmetics sector is expected to continue its decade-long success. Since a few decades ago, non-surgical procedures have grown, including wrinkle relaxers and dermal filler injections. This evolution is primarily attributable to technology benefits, including quick healing, less blood loss, decreased infection risk, and cheaper overall treatment costs. Thus, during the projection period, the market expanded along with the rise in cosmetic procedures.
More eminent firms have joined the cosmetic injectables industry due to the promising developments in usage. To provide unique fillers that satisfy unmet consumer needs, these businesses have worked on several research & development projects. As a result, innovative products have been released, and procedure volumes have increased globally. Throughout the forecast period, these favorable aspects are anticipated to have a substantial impact on the growth of the market. Also, the rising use of these types of goods by people of all ages is another significant market trend that is anticipated to support the market's rise.
Given that China and India are two of the world's most populous nations, the region's elderly population is growing rapidly. India, the second-most populous country in the world, has experienced a dramatic demographic transition over the past 50 years, with the old population nearly tripling, according to the National Library of Medicine. The organization also estimated that by 2025, there would be 158.7 million elderly people in India and that by 2050, they would outnumber children under 14. The prevalence of fine lines, wrinkles, and other aging signs is predicted to increase considerably in the area with an increase in the older population. Because of this, it is anticipated that the market for facial injectables in the APAC region will expand throughout the projected period.
The China market dominated the Asia Pacific Facial Injectable Market by Country in 2022 thereby, achieving a market value of $1,726 Million by 2029. The Japan market is exhibiting a CAGR of 10.4% during (2023 - 2029). Additionally, The Taiwan market would experience a CAGR of 11.8% during (2023 - 2029).
Based on End-use, the market is segmented into MedSpa, Dermatology Clinics and Hospitals. Based on Product, the market is segmented into Botulinum Toxin Type A, Calcium Hydroxylapatite (CaHA), Poly-L-Lactic Acid (PLLA), Collagen & PMMA Microspheres, Hyaluronic Acid (HA) and Others. Based on Application, the market is segmented into Facial Line Correction, Face Lift, Lip Augmentation, Acne Scar Treatment, Lipoatrophy Treatment and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Taiwan, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Facial Injectable Market is Projected to reach USD 22.5 Billion by 2029, at a CAGR of 10.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Ipsen Pharma Biotech SAS, Merz Pharma GmbH & Co. KGaA, Suneva Medical, Inc., Medytox Inc., Sinclair Pharma Ltd., Bloomage Biotechnology Corporation Limited (Bloomage International Investment Group), Anika Therapeutics, Inc., Prollenium Medical Technologies Inc., Galderma S.A., and Allergan PLC (AbbVie, Inc.).
By End-use
By Product
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
